Immunotherapy + Chemoradiotherapy Could Lead to More Effective Treatment of Resectable Locally Advanced Esophageal Squamous Cell Carcinoma
Dr. Xuefeng Leng from Sichuan Cancer, Hospital & Institute located in Chengdu, China present in this MEDtalks the results from his late breaking abstract presented at ACCO GI 2025. This is the first three-arm randomized trial to evaluate immunotherapy-based combination treatment modalities against a standard neoadjuvant chemotherapy in locally advanced esophageal squamous cell carcinoma.
In the MEDtalk Dr. Xuefeng Leng emphasize that the results of the study show that immunotherapy + chemoradiotherapy could lead to more effective treatment of resectable locally advanced esophageal squamous cell carcinoma.
Få tilgang
Hvis du er lege, sykepleier eller annen helsepersonell, kan du få tilgang til hele artikkelen ved å opprette en profil på BestPractice Nordic.
- Få tilgang
- Hvis du allerede har en profil: Logg in